European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer

On 1 February 2013, a marketing authorisation valid throughout the European Union was issued for aflibercept (Zaltrap) in combination with irinotecan/5-fluorouracil/folinic acid chemotherapy for the treatment of adults with metastatic colorectal cancer resistant to or progressive after an oxaliplati...

Descripción completa

Detalles Bibliográficos
Autores principales: Stanel, Stefan Cristian, Sjöberg, Jan, Salmonson, Tomas, Foggi, Paolo, Caleno, Mariapaola, Melchiorri, Daniela, Gravanis, Iordanis, Tzogani, Kyriaki, Pignatti, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: ESMO Open 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519808/
https://www.ncbi.nlm.nih.gov/pubmed/28761750
http://dx.doi.org/10.1136/esmoopen-2017-000190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519808/
https://www.ncbi.nlm.nih.gov/pubmed/28761750
http://dx.doi.org/10.1136/esmoopen-2017-000190

Ejemplares similares